Sahajanand Medical Technologies IPO Details
Sahajanand Medical Technologies IPO Summary
Sahajanand Medical Technologies IPO opens for subscription on 15 Oct 2026 and closes on 19 Oct 2026.The IPO will be listed on NSE, BSE with the tentative listing date set for 23 Oct 2026.
Sahajanand Medical Technologies IPO price band has been fixed at ₹327 – ₹344 per share. The face value is ₹1 per share with a lot size of 43.
Sahajanand Medical Technologies IPO total issue size comprises 1,38,22,116 shares (aggregating up to ₹475.48 Cr). Offer for Sale consists of 1,38,22,116 shares (aggregating up to ₹475.48 Cr). Pre-issue shareholding stands at 10,16,46,778, which will increase to 10,16,46,778 post-issue.
Sahajanand Medical Technologies IPO carries a ₹17 (4.94%) GMP, reflecting investor sentiment.
Sahajanand Medical Technologies IPO Lot Size :Retail Minimum is 1 lot (43 shares) amounting to ₹14,792. Retail Maximum is 13 lots (559 shares) amounting to ₹1,92,296. SHNI Minimum is 14 lots (602 shares) amounting to ₹2,07,088. SHNI Maximum is 67 lots (2,881 shares) amounting to ₹9,91,064. BHNI Minimum is 68 lots (2,924 shares) amounting to ₹10,05,856.
Sahajanand Medical Technologies IPO Details
Sahajanand Medical Technologies IPO Subscription
Sahajanand Medical Technologies IPO Application Wise Breakup (Approx)
Sahajanand Medical Technologies IPO Dates
- 15 Oct 2026Opening dateOpen
- 19 Oct 2026Closing dateClose
- 21 Oct 2026Allotment Date Allotment
- 22 Oct 2026Initiation of RefundsRefund
- 22 Oct 2026Credit of SharesCredit
- 23 Oct 2026Listing dateListing
Sahajanand Medical Technologies IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 43 | ₹14,792 |
| Retail Maximum | 13 | 559 | ₹1,92,296 |
| SHNI Minimum | 14 | 602 | ₹2,07,088 |
| SHNI Maximum | 67 | 2881 | ₹9,91,064 |
| BHNI Minimum | 68 | 2924 | ₹10,05,856 |
Sahajanand Medical Technologies IPO Reservation
Promoter Holding
Documents
Sahajanand Medical Technologies IPO Valuations
Sahajanand Medical Technologies Financial Information
| Period Ended | 30 Jun 2026 | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|---|
| Assets | 1,309.00 | 1,276.43 | 1,094.90 | 970.58 |
| Total Income | 354.33 | 1,218.73 | 1,035.96 | 908.59 |
| Profit After Tax | 15.09 | 69.08 | 25.15 | -7.35 |
| EBITDA | 48.58 | 170.66 | 128.02 | 110.05 |
| NET Worth | 631.72 | 616.05 | 545.23 | 526.30 |
| Reserves and Surplus | 706.86 | 692.48 | 580.71 | 556.57 |
| Total Borrowing | 320.63 | 269.53 | 224.96 | 175.27 |
| Amount in ₹ Crore | ||||
About Sahajanand Medical Technologies IPO
Founded in 2001 by Mr. Dhirajlal Kotadia, Sahajanand Medical Technologies Ltd. is a medical device company focused on Class III and Class C/D devices, primarily in the fields of vascular and structural heart intervention. The company was the first globally to receive CE certification for a drug-eluting stent (DES) with a biodegradable polymer—Infinnium.
The product portfolio spans three key categories:
- Vascular Intervention (VI): Includes coronary stents and balloons for minimally invasive blood vessel treatments.
- Structural Heart (SH): Covers advanced technologies such as Transcatheter Aortic Valve Implantation (TAVI) and Occluders.
- Other Products: Includes renal stents, peripheral Drug-Coated Balloons (DCBs), and selected trading products.
Sahajanand operates two R&D centers—one in India and one in Thailand—supported by a team of 102 professionals, including biomedical engineers and clinical research specialists. The company has built a robust intellectual property base, with 102 patents granted globally and 71 pending patent applications, along with five design registrations in India.
Key products such as Supraflex Cruz (DES), Hydra (TAVI), and Cocoon (Occluders) are backed by 72 clinical studies, and are widely accepted in over 76 countries across Europe, Asia, and other regions. The global distribution strategy includes direct operations in key European markets (Germany, Spain, France, UK), hybrid models in India (serving hospitals like Narayana Hrudayalaya Limited), and distributor-led entry in markets such as Italy.
International market adoption is reinforced by endorsements from key opinion leaders (KOLs), successful government tenders, and partnerships with major Group Purchasing Organizations (GPOs) in Europe.
The company follows a “House of Brand” strategy, developing and commercializing clinically differentiated products under recognized brand names like Supraflex Cruz, Hydra, and Cocoon.
As of March 31, 2025, Sahajanand Medical Technologies employed 1,458 full-time staff, 24 consultants, and 818 contract-based personnel across its operations.
Strength Of Sahajanand Medical Technologies IPO
- Technologically advanced products in segments with high entry barriers.
- Proven research and development capabilities across products categories and platform technologies.
- Leadership in India and key international markets across products.
- Deep global sales and marketing presence leading to fast growth in diversified international markets.
- Diversified, integrated, and efficient manufacturing facilities accredited by regulatory authorities.
Risk Of Sahajanand Medical Technologies IPO
- The company is subject to extensive regulatory requirements in applicable jurisdictions. Any adverse action by any authority against the company would negatively impact its ability to offer the company's products to the company's clients and adversely impact its business and prospects.
- The company's manufacturing facilities are subject to certain risks, including quality control issues, disruptions in infrastructure facilities, and obsolete plant and machinery, which could increase its manufacturing costs or interrupt the company's operations and adversely impact its reputation, sales and strategies.
- The company is required to obtain, renew or maintain statutory and regulatory permits, licenses and approvals in relation to the company's manufacturing facilities, and any delay or inability in obtaining, renewing or maintaining such permits, licenses and approvals could result in an adverse effect on its business, financial condition, cash flows and results of operations. Further, the company's manufacturing facilities are subject to periodic inspections and audits by various regulatory authorities and clients.
- The company is dependents on the continued supply of raw materials and components, the supply and cost of which can be subject to significant variation due to factors outside our control. Additionally, the company is dependent on the company's suppliers (our top 10 suppliers contributed to 64.37%, 58.88% and 62.87% of total purchases in Fiscal 2025, Fiscal 2024 and Fiscal 2023, respectively) for certain raw materials and components and a single supplier for certain components and an inability to procure the required quality and quantity, at competitive prices, the company's business, financial condition, cash flows and results of operations may be adversely affected.
- A majority of the company's revenues are from the sale of Vascular Intervention devices (contributed to 65.86%, 68.57% and 71.99% of its revenue from operations in Fiscals 2025, 2024 and 2023, respectively). Additionally, the sale of the Supraflex Cruz contributed to 42.06%, 47.84% and 44.91% of the company's revenue from operations in Fiscals 2025, 2024 and 2023, respectively. Any adverse impact on sales of products within this vertical, or of the Supraflex Cruz would adversely affect its business, results of operations and profitability.
- The company may not be able to implement its business strategies or sustain and manage the company's growth.
- Regulatory uncertainty associated with pricing of medical devices could adversely affect the marketing, pricing and demand for our products, which may affect its financial condition and results of operations.
- The company is exposed to foreign currency exchange rate fluctuations.
- The company's inability to expand or effectively manage its growing distribution network may have an adverse effect on the company's business, results of operations and financial condition.
- The company faces intense competition and may be unable to adapt to the rapid technological changes in the medical devices industry, which could adversely affect its business, results of operations and financial conditions.
Objectives Sahajanand Medical Technologies IPO
1. The company will not receive any proceeds from the Offer.
Company Contact Details
Sahajanand Medical Technologies Ltd.
Sahajanand Estate, Wakharia Wadi,
NR. Dabholi Char Rasta
Nani Ved, Ved Road
Surat, Gujarat, 395004
Phone: 022 49564000
Email: investors.grievance@smt.in
Website: http://www.smtpl.com/
Registrar Contact Details
Sahajanand Medical Technologies FAQs
The Sahajanand Medical Technologies IPO is a MAINBOARD public issue comprising 13822116 equity shares with a face value of ₹1 each, aggregating to a total issue size of ₹475.48 Cr. The issue price has been fixed at ₹344 per equity share, and the minimum application size is 43 shares.
The IPO opens for subscription on 15 Oct 2026, and closes on 19 Oct 2026.
MUFG Intime India Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at ₹17 (4.94%).
Quick Links
Comments
